GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Revenue per Share

Galapagos NV (Galapagos NV) Revenue per Share

: $3.82 (TTM As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Galapagos NV's revenue per share for the three months ended in Dec. 2023 was $-3.48. Galapagos NV's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.82.

Warning Sign:

Galapagos NV revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Galapagos NV was -0.90% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -20.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -17.30% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Galapagos NV's Revenue per Share or its related term are showing as below:

GLPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40   Med: 3.7   Max: 69.9
Current: -20.9

During the past 13 years, Galapagos NV's highest 3-Year average Revenue Per Share Growth Rate was 69.90% per year. The lowest was -40.00% per year. And the median was 3.70% per year.

GLPG's 3-Year Revenue Growth Rate is ranked worse than
78.88% of 767 companies
in the Biotechnology industry
Industry Median: 4.7 vs GLPG: -20.90

Galapagos NV Revenue per Share Historical Data

The historical data trend for Galapagos NV's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.43 8.94 4.04 3.89 3.97

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.95 2.89 2.49 1.93 -3.48

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's PS Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's PS Ratio falls into.



Galapagos NV Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Galapagos NV's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=261.422/65.884
=3.97

Galapagos NV's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=-228.052/65.470
=-3.48

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (NAS:GLPG) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Galapagos NV Revenue per Share Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.